Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Gastric Cancer
Published in:

11-04-2024 | Gastric Cancer | Letter to the Editor

Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer

Authors: Hyung-Don Kim, Min-Hee Ryu, Ji Sung Lee, Yoon-Koo Kang

Published in: Gastric Cancer | Issue 4/2024

Login to get access

Excerpt

Yoshikawa et al. have reported on the long-term follow-up results of the OPAS-1 trial in gastric cancer [1]. The authors compared 4 vs. 8 courses of adjuvant S-1 after radical gastrectomy in patients with pathological stage II gastric cancer. The 5-year overall survival (OS) rates were 89.7% and 88.6% for the 8-course and 4-course arms, respectively, with a hazard ratio (HR) for OS in the 4-course arm of 1.121 (95% confidence interval 0.719–1.749). Based on these results, the authors concluded that an 8-course regimen of adjuvant S-1 should remain the standard adjuvant chemotherapy for pathological stage II gastric cancer. However, there are some issues that need to be considered while interpreting these results. …
Literature
1.
2.
3.
4.
5.
Metadata
Title
Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer
Authors
Hyung-Don Kim
Min-Hee Ryu
Ji Sung Lee
Yoon-Koo Kang
Publication date
11-04-2024
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 4/2024
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-024-01496-4

Other articles of this Issue 4/2024

Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination

Early gastric cancer with RhoGAP fusion is linked to frequent nodal metastasis and a part of microtubular–mucocellular histology

Global burden of young-onset gastric cancer: a systematic trend analysis of the global burden of disease study 2019

Development of a reliable surgical quality assurance tool for gastrectomy in oncological trials

Risk prediction model for gastric cancer within 5 years in healthy Korean adults

Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar
Image Credits